ClinicalTrials.gg
RecruitingNCT07227168Updated Aug 27, 2026

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

A Phase 1 interventional study of STRO-004 and Pembrolizumab in Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC and Esophageal Cancer, sponsored by Sutro Biopharma, Inc.. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Sutro Biopharma, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 676 studies in Esophageal Neoplasms with a site in United States — 122 open to participants now, 172 under way, 2 of them phase 3. Esophageal Neoplasms · United States.

Planned enrollment
70th of 525
200 · median 42
Started
2025
with 27 others
Phase 1
167 of 676
29 open now
Primary completion
2027-12
later than 96 of 170 live
Registered
654th of 676
by date

Among the 676 studies in Esophageal Neoplasms with a site in United States, this one is the 70th largest by planned enrollment of the 525 interventional ones that give a count, is one of 28 that started in 2025, is one of 167 in phase 1, reaches primary completion later than 96 of the 170 other live ones, and was the 654th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 503 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

122 of the 676 studies in Esophageal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 388 Esophageal Neoplasms studies recruiting now, 246 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 676 studies in Esophageal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts:

  • Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF).
  • Part 1B is a cohort expansion in 1 or more types of cancer to further evaluate a STRO-004 monotherapy dose, determine the best dose for use in later phases, and examine anti-tumor activity.
  • Part 1C is a dose escalation of STRO-004 combined with pembrolizumab to determine tolerability and preliminary anti-tumor activity of both drugs used together.
03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma HNSCC
  • Non-Small Cell Lung Cancer NSCLC
  • Esophageal Cancer
  • Gastric Cancer
  • Colorectal Cancer
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Cervical Cancer
  • Endometrial Cancer
  • Urothelial Cancer

Keywords

  • Tissue Factor (TF)
  • STRO-004
  • Antibody Drug Conjugate
  • ADC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically documented or locally advanced solid tumors including: Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Esophageal/Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Cervical Cancer, Endometrial Cancer, and Urothelial Carcinoma
  • Age 18 years or older
  • (ECOG) performance status 0 to 1
  • Received all appropriate systemic therapies that are locally available for which they are eligible. For Parts 1A and 1C, there is no limit on the number of prior therapies. For Part 1B only, up to 3 prior therapies are allowed, except for NSCLC participants with genomic alterations, who may have up to 4 prior therapies
  • Availability of tumor tissue
  • per 1.1
  • Adequate organ function
  • Participants receiving anticoagulants must be on a stable dose

Exclusion criteria

Exclusion Criteria:

  • Eye disorders
  • Untreated
  • Pre-existing ocular disorders, active interstitial lung disease, clinically significant cardiac or cerebrovascular disease, or other significant concurrent, uncontrolled medical condition
  • Previous solid organ or bone marrow transplantation
  • Concurrent participation in another therapeutic treatment trial
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Part 1A STRO-004 Monotherapy

    Drug: STRO-004

  • Experimental
    Part 1B STRO-004 Monotherapy

    Drug: STRO-004

  • Experimental
    Part 1C STRO-004 in Combination with Pembrolizumab

    Drug: STRO-004 · Drug: Pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1A: Number of participants with Dose-limiting Toxicities (DLTs)

    Time frame: Up to Day 21

  2. Part 1A, 1B: Percentage of participants with Treatment-Emergent Adverse Events (TEAEs), with severity determined according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grading scale

    Time frame: Up to 12 Months

  3. Part 1A, 1B, 1C: Percentage of participants with clinical laboratory abnormalities, with severity determined according to the CTCAE v5.0 grading scale

    Time frame: Up to 12 months

  4. Part 1B: Objective Response Rate (ORR)

    Best response of Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1)

    Time frame: Up to 12 months

  5. Part 1B: Disease control rate (DCR)

    The proportion of participants with best response of CR, PR or Stable Disease (SD) per RECIST V1.1

    Time frame: Up to 12 months

  6. Part 1B: Duration of Response (DOR)

    Time from first occurrence of objective response to the time of Progressive Disease (PD) according to RECIST v1.1 or death from any cause, whichever comes first

    Time frame: Up to 12 months

  7. Part 1B: Progression-Free Survival (PFS)

    Time from first dose to the first occurrence of PD according to RECIST v1.1 or death from any cause, whichever comes first

    Time frame: Up to 12 months

  8. Part 1B: 12-month survival rate

    Percentage of participants alive 12 months after first dose of study treatment

    Time frame: 12 months

  9. Part 1C: Percentage of participants with TEAEs, with severity determined according to the CTCAE v5.0 grading scale

    Time frame: Up to 12 months

Secondary outcomes

  1. Part 1A, 1B, 1C: Plasma concentrations of STRO-004 and its metabolites at specified timepoints

    Time frame: Up to 12 months

  2. Part 1A, 1B, 1C: Immunogenicity

    As measured by circulating antidrug antibody (ADA) over time

    Time frame: Up to 12 months

  3. Part 1A: Objective Response Rate (ORR)

    Up to 12 months

    Time frame: Best response of CR or PR per RECIST V1.1

  4. Part 1A, 1C: Disease Control Rate (DCR)

    Proportion of participants with best response of CR, PR or SD per RECIST V1.1

    Time frame: Up to 12 months

  5. Part 1A, 1C: Duration of Response (DOR)

    Time from first occurrence of objective response to the time of PD according to RECIST v1.1 or death from any cause, whichever comes first

    Time frame: Up to 12 months

  6. Part 1A,1C: Progression-Free Survival (PFS)

    Time from first dose to the first occurrence of PD according to RECIST v1.1 or death from any cause, whichever comes first

    Time frame: Up to 12 months

  7. Part 1A,1C: 12-month survival rate

    Proportion of participants alive 12 months after the date of first dose of study treatment

    Time frame: 12 months

07

Study locations

9 of 9 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.

Of 78 industry-sponsored phase 1 interventional studies under Esophageal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 70. This study's planned 25 months is below that.

Counting every sponsor, half of 126 studies reached it within 48 months; a quarter within 29 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2025
First posted
Nov 12, 2025
StartActual
Nov 7, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Apr 2028
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07227168
Lead sponsor
Sutro Biopharma, Inc.
Responsible party
Sponsor
First posted
Nov 12, 2025
Start date
Nov 7, 2025
Primary completion
Dec 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Aug 27, 2026

Study contacts

Sutro Clinical Development
Contact
ClinicalTrials@sutrobio.com
650-801-6416

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion